Plasma vaspin is an effective biomarker for evaluation of future cardiovascular events in patients with chest pain: a 5-year retrospective observational study

Shuya Ji, Wenxin Kou, Peipei Luan, Weixia Jian, Jianhui Zhuang, Xiaopeng Xu, Yifan Zhao, Hailing Li, Wenhui Peng

1Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072 China; 2Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200000, China

Contributions: (I) Conception and design: H Li, W Peng; (II) Administrative support: W Peng; (III) Provision of study materials or patients: Y Zhao, X Xu; (IV) Collection and assembly of data: J Zhuang, W Jian, P Luan; (V) Data analysis and interpretation: S Ji, W Kou; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

These authors contributed equally to this work.

Background: Our previous study showed that visceral adipose tissue-derived serpin (vaspin) was an independent predictor of coronary artery disease (CAD). Further, plasma vaspin levels in patients with unstable angina pectoris were lower than those in patients with stable angina pectoris. In this study, we investigated the prognostic relevance of plasma vaspin levels in patients with CAD and non-CAD.

Methods: It was a retrospective observational study. A total of 197 patients with chest pain were enrolled, of which 88 patients with CAD and 109 patients with non-CAD were confirmed by angiography. Plasma vaspin levels and clinical parameters were measured at baseline. Incidence of major adverse cardiac event (MACE) was determined on follow-up.

Results: One hundred eighty-nine patients were successfully followed up for 5 years, of which 63 patients experienced MACEs. Patients with low vaspin levels (<0.385 ng/mL) experienced a higher incidence of MACE as compared to patients with high vaspin levels (>0.385 ng/mL) (42.55% vs. 24.21%, respectively; P=0.007). In both CAD and non-CAD groups, patients with high vaspin levels showed improvement in left ventricular ejection fraction. Kaplan Meier survival curves showed that patients with low vaspin levels had an obviously higher timing of incidence of MACE in the whole population (P=0.006) and in the non-CAD subgroup (P=0.009); however, the trend was not significant in the CAD subgroup. On multivariate analyses, plasma vaspin level was found to be an independent predictor of MACE, particularly in the non-CAD group.

Conclusions: Plasma vaspin may be a useful biomarker for prediction of MACE in patients with chest pain.

Keywords: Plasma vaspin; biomarker; prognosis; major adverse cardiac events; coronary artery disease

Introduction

Adipose tissue is now regarded not only as an energy reservoir, but also as an active endocrine organ, which can secrete a variety of metabolically-active adipocytokines. Some adipokines have even been linked with metabolic diseases; for instance, adiponectin has been shown to be a robust biomarker of insulin sensitivity (1,2).

Visceral adipose tissue-derived serpin (vaspin), a member of the serine protease inhibitor family, is a novel adipokine
isolated from a rat model of abdominal obesity with type 2 diabetes mellitus (T2DM) (3). Previous studies showed an association between vaspin concentration and metabolic disorders, including T2DM, cardiovascular diseases (CVDs) (4-6), polycystic ovary syndrome (7), and osteoarthritis (8). Plasma vaspin concentration was showed to correlate with body mass index (BMI), gender, and physical training. An earlier study suggested a causal relationship of plasma vaspin levels with obesity (9). Also, a recent research indicated that vaspin protected against high fat diet induced bone loss, and promoted osteogenic differentiation (10). Up-regulation of vaspin was showed to protect against insulin resistance by activating the IRS/PI3K/Akt/Insulin receptor 4 and inhibiting the IkBa/NF-kB signaling pathway (11). Besides, in our previous studies, patients with low concentration of vaspin were found to be at a higher risk of coronary artery disease (CAD) and acute coronary syndrome (ACS) (12,13). Further, lower concentration of vaspin was associated with poor prognosis in patients with myocardial infarction (14).

Based on these data, it is conceivable that vaspin plays an important role in the development of atherosclerosis. In our previous animal studies, vaspin was showed to protect against atherosclerosis through inhibition of vascular smooth muscle cell proliferation and chemokines is owing to decreased production of reactive oxygen species and downregulation of NF-kB signaling pathways (15). In a study by Yuan et al., vaspin played a role of cardioprotective function by down-regulating the expression of toll-like receptor 4 and inhibiting the phosphorylation of NF-kB in myocardial ischemia reperfusion injury rats and hypoxia-re-oxygenation induced H9C2 cells (16).

These findings prompted us to further investigate the potential association between vaspin levels and prognosis of patients with CVDs. Also, although some patients with chest pain were excluded CAD by angiography, previous studies found that these patients still have a risk of major adverse cardiac events (MACEs) (17). Moreover, only a limited blood biomarker was used to predict prognosis in these patients. The present study focused on the prognostic value of plasma concentration of vaspin in patients with no angiographic evidence of CAD. Furthermore, we also sought to assess whether plasma vaspin could predict events after 5 years, as 5-year follow-up is considered as a key point for evaluation of biomarkers (18). Furthermore, patients with negative coronary angiography (CAG) may also have poor prognosis, as these patients may have other risk factors such as hypertension, and diabetes. It is also important to explore whether vaspin would be an effective biomarker of prognostic relevance in this subpopulation.

Methods

Study population

A total of 197 patients who presented with chest pain at the Department of Cardiology, at the Shanghai Tenth People’s Hospital between June 2010 and December 2011 were enrolled in this study. Patients with chest pain caused by pulmonary embolism, pneumonia, pneumothorax, pleural disease, rib disease, digestive system disease, and neurological pain were excluded. The diagnosis of CAD was based on CAG findings of at least one coronary stenosis ≥50%. In CAD group, the population contains stable CAD or unstable angina. Patients were diagnosed with unstable angina if they had chest pain that was new in onset or if they had a significant unexplained change in the pattern of stable angina (such as increased frequency, increased intensity, increased duration or decreased response to nitrates) in the previous 2 months (19). Patients with acute myocardial infarction (troponin T ≥0.10 ng/mL), acute or chronic heart failure [left ventricular ejection fraction (LVEF) <40%], cardiomyopathy, acute infection (Temperature >38.5 °C), acute exacerbation of chronic infectious or inflammatory diseases, severe liver dysfunction (alanine transaminase >3 times upper normal limit), renal dysfunction (creatinine >132 μmol/L) and malignancy were excluded. All study participants underwent a standard clinical examination, including medical history, physical examination, chest radiograph or computed tomography (CT), Echocardiography, biochemical examination which contained D-dimmer, troponin T and pro-BNP etc. If the patient’s D-dimmer was significantly increased, the pulmonary artery computed tomography angiography (CTA) would be further used to determine if there was pulmonary embolism. Pneumonia, pneumothorax and pleural diseases were diagnosed according to the chest radiograph or CT. Digestive system disease, and neurological pain and rib disease were diagnosed according to the history of digestive diseases, a history of herpes zoster, medication and characteristics of physical examination, etc. BMI was calculated as weight divided by the square of height. Hypertension was defined as highest blood pressure ≥140/90 mmHg or history of anti-hypertensive therapy. The diagnoses of diabetes were based on the diagnostic criteria recommended by the World Health Organization (WHO) (20). Written informed consent was obtained from
all patients prior to their enrolment. The study protocol was approved by the Ethics Committee at the Shanghai Tenth People’s Hospital.

**Coronary angiography**

All patients enrolled in this study were undergone CAG, which was performed through a radial artery with standard Judkins technique. Significant CAD was diagnosed as the presence of at least one of luminal diameter stenosis ≥50% including the left anterior descending artery, right coronary artery, left circumflex coronary artery and their main branches. All imaging analyses were performed by two professional interventional cardiologists.

**ELISA assays, biochemical investigations and echocardiographic assessment**

Approximately 5 mL whole blood samples were extracted prior to CAG. Plasma was isolated from blood samples after a 10-hour overnight fast and then stored at -80°C until further processing. Human vaspin (Adipogen, Seoul, South Korea) plasma levels were measured with commercially available ELISA kit, according to the manufacturers’ instructions. The sensitivity of the vaspin ELISA was 12 pg/mL. The intra-assay coefficient of variance (percent) of the ELISA system ranged from 1.31% to 1.74%, while the inter-assay coefficient of variance ranged from 5.9% to 8.3%. White blood cell count (WBC), high sensitive C-reactive protein (hsCRP), glycosylated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured by colorimetric enzymatic assay systems (Roche MODULAR P-800, Swiss Confederation).

All subjects were performed transthoracic echocardiography by an echocardiograph equipped with a broadband transducer (Vivid 7ª, GE VingMed Ultrasound AS; Horten, Norway). Measurement of LVEF was obtained from the modified Simpson rule in the apical two- and four-chamber views.

**Follow-up**

It was a retrospective observational study. Follow-up data were obtained through the following four ways: hospital record review, telephonic contact, outpatient visits and rehospitalization. Follow-up data was collected up to December 31, 2015. The duration of follow-up was 5 years.

The primary endpoint was MACE, which included cardiac death, non-fatal myocardial infarction, revascularization with percutaneous coronary intervention or coronary artery bypass grafting, ischemic stroke, or rehospitalization for severe angina. Non-fatal myocardial infarction was defined as a rise of troponin T ≥0.1 ng/mL along with canonical chest pain symptoms and/or characteristic electrocardiographic changes. Deaths caused by accidents were excluded (follow-up censored at the time of death) (14,17). The median concentration of vaspin was 0.385 ng/mL. All patients were categorized into two subgroups according to the median value.

**Statistical analysis**

Continuous variables are expressed as mean ± standard deviation. Categorical variables are presented as frequencies and percentages. For continuous variables, normal distribution was verified with the Kolmogorov-Smirnov test. Comparisons between groups were made using independent t-test, ANOVA, the nonparametric Mann-Whitney U test or Kruskal-Wallis test as appropriate. For categorical clinical variables, Chi-square test or Fisher exact test was employed. For a P value<0.05 was considered indicative of a statistically significant between-group difference. The Kaplan-Meier method was used to analyze the timing of events during follow-up. Statistical assessment was performed with the log-rank test and P<0.05 was considered significant. Univariate and multivariate analyses were performed using a Cox proportional hazards model to determine the predictors of the primary endpoint. The explanatory variables were used in the univariate analyses. Explanatory variables that were associated with P values <0.1 on univariate analyses were included in the multivariate analysis. All analyses were performed with SPSS 20 (SPSS Inc., IL, USA).

**Results**

**Baseline characteristics of the study population in CAD and non-CAD groups**

The baseline characteristics of the subjects are showed in Table 1. In brief, a total of 197 patients (112 men and 85 women) were enrolled. They were divided into two groups according to CAG findings: CAD (n=88) and non-CAD (n=109). A total of 30 CAD patients were performed percutaneous coronary intervention (PCI). The mean
concentration of plasma vaspin in the CAD group was lower than that in the non-CAD group (0.63±0.95 vs. 1.07±2.12 ng/mL, P=0.037). No significant between-group differences were observed with respect to age, gender, BMI, smoking, coronary risk factors, TG, HDL-C and HbA1c levels. Serum hsCRP levels (11.52±5.77 vs. 6.51±6.05 mg/L,

| Characteristics | CAD (n=88) | Non-CAD (n=109) | P value |
|-----------------|-----------|-----------------|---------|
| Age, year       | 65±10     | 65±12           | 0.923   |
| Male, n (%)     | 56 (63.64%) | 56 (51.38%) | 0.086   |
| BMI, kg/m²      | 24.34±3.85 | 24.49±3.61 | 0.793   |
| Coronary risk factors |             |                 |         |
| Smoking, n (%)  | 21 (23.86%) | 18 (16.51%) | 0.198   |
| Diabetes, n (%) | 23 (26.14%) | 22 (20.18%) | 0.322   |
| Hypertension, n (%) | 59 (67.05%) | 67 (61.47%) | 0.418   |
| SBP (mmHg)      | 142.43±22.65 | 144.93±24.29 | 0.462   |
| DBP (mmHg)      | 81.27±11.55 | 81.86±13.95 | 0.752   |
| Hyperlipidemia, n (%) | 11 (12.50%) | 12 (11.01%) | 0.746   |
| Laboratory data |             |                 |         |
| Total cholesterol (mmol/L) | 4.37±1.11 | 4.77±0.95 | 0.009*  |
| Triglyceride (mmol/L) | 1.68±0.81 | 2.24±6.10 | 0.411   |
| HDL-C (mmol/L)   | 1.11±0.32 | 1.23±0.49 | 0.057   |
| LDL-C (mmol/L)   | 2.45±0.90 | 2.72±0.78 | 0.038*  |
| HbA1c (%)        | 5.87±2.05 | 5.79±1.91 | 0.800   |
| White blood cell count (10⁹/L) | 6.17±1.79 | 6.38±2.09 | 0.479   |
| hsCRP (mg/L)     | 11.52±5.77 | 6.51±6.05 | <0.001* |
| ProBNP (pg/mL)   | 543.03±1,097.31 | 276.68±445.34 | 0.048*  |
| Medications      |             |                 |         |
| Statins, n (%)   | 20 (22.73%) | 5 (4.59%) | <0.001* |
| Insulin, n (%)   | 3 (3.41%) | 6 (5.50%) | 0.721   |
| ACEI/ARB, n (%)  | 13 (15.12%) | 14 (15.38%) | 0.960   |
| CCB, n (%)       | 19 (22.09%) | 17 (18.68%) | 0.573   |
| β blocker, n (%) | 6 (6.98%) | 5 (5.49%) | 0.683   |
| LVEF (%)         | 58.9±18.0 | 54.6±23.6 | 0.180   |
| ACS (%)          | 24 (29.63%) | 0 (0) | <0.001* |
| Vaspin (ng/mL)   | 0.63±0.95 | 1.07±2.12 | 0.037*  |

Continuous variables were described as mean ± standard deviation; categorical variables were presented as frequencies. CAD, coronary artery disease; n, number of patients; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycosylated haemoglobin; hsCRP, high sensitivity C reactive protein; proBNP, Pro-Brain Natriuretic Peptide; ACEI/ARB, angiotensin-converting enzyme inhibitor and angiotensin receptor block agent; CCB, calcium channel blocker; WBC, white blood cells count; LVEF, left ventricular ejection fraction; ACS, acute coronary syndrome. *P<0.05.
respectively; P<0.001) and frequency of statin usage in the CAD group were higher than that in the non-CAD group. On the contrary, serum TC and LDL-C concentrations in the non-CAD group were higher than those in the CAD group (Table 1).

Baseline characteristics of the study population disaggregated by vaspin levels

The median concentration of vaspin was 0.385 ng/mL. All patients were categorized into two subgroups according to the median value. In the CAD group, non-smokers had higher concentrations of vaspin as compared to that in smokers (34.78% vs. 11.90%, respectively; P=0.012) (Table 2). The percentage of male patients in the low-vaspin subgroup was significantly higher than that in the high-vaspin subgroup (73.91% vs. 52.38%, respectively; P=0.036). However, no significant between-group differences of cardiovascular history, such as ACS, post-PCI or coronary artery bypass graft (CABG), number of vascular lesions and degree of lesions were observed in CAD group. In the non-CAD group, higher HDL-C and insulin administration were found in high-vaspin subgroup; however, this subgroup had lower LVEF as compared to that in the low-vaspin sub-group (50.6%±27.2% vs. 59.9%±16.5%, respectively; P=0.046).

Relationship of plasma vaspin levels with 5-year MACE

Eight patients were lost to 5-year follow-up. Among these, 4 patients were men and 4 patients were diagnosed with CAD. At 5-year follow-up, serum TC levels in the high-vaspin subgroup were significantly decreased in CAD group but not in the non-CAD group, as patients with CAD usually received statin therapy. Of note, high-vaspin subgroups in both the CAD and non-CAD groups showed improved cardiac LVEF (55.8%±21.7% to 64.5%±9.1% and 50.6%±27.2% to 65.1%±6.2%, respectively; P<0.05 for all). This phenomenon was not observed in low-vaspin subgroups in the two groups (Table S1).

Although the total MACE between CAD and non-CAD groups has insignificantly difference, we found that the number of patients who experienced multiple times of MACEs in CAD group is more than non-CAD group, which could indicate that the patients with CAD has a higher risk of MACE than patients in non-CAD group. Also, we found that low- and high-vaspin subgroups of the CAD group had comparable incidence of MACE (P=0.264); however, more patients in the low-vaspin subgroup received revascularization treatment as compared to that in the high-vaspin subgroup [13 (28.26%) vs. 3 (7.89%), P=0.018]. Incidence of new-onset diseases such as diabetes or hypertension was comparable between the low- and high-vaspin subgroups in both CAD and non-CAD groups.

| Characteristics            | CAD (n=88) | Non-CAD (n=109) |
|----------------------------|------------|-----------------|
| Age, year                  | 64±10      | 67±11           |
| Male, n (%)                | 34 (73.91%)| 29 (60.42%)     |
| BMI, kg/m²                 | 24.36±4.09 | 25.12±3.37      |
| Smoking, n (%)             | 16 (34.78%)| 7 (14.58%)      |
| Diabetes, n (%)            | 11 (23.91%)| 8 (16.67%)      |
| Hypertension, n (%)        | 29 (63.04%)| 33 (68.75%)     |
| SBP (mmHg)                 | 141.98±23.86| 148.15±24.84   |
| DBP (mmHg)                 | 83.00±13.22| 81.27±15.15    |

Table 2 (continued)
| Characteristics                        | CAD (n=88) | Non-CAD (n=109) | P value | CAD (n=88) | Non-CAD (n=109) | P value |
|----------------------------------------|------------|-----------------|---------|------------|-----------------|---------|
|                                        | Vaspin <0.385 (n=46) | Vaspin >0.385 (n=42) |         | Vaspin <0.385 (n=49) | Vaspin >0.385 (n=60) |         |
| **Laboratory data**                    |            |                 |         |            |                 |         |
| Total cholesterol (mmol/L)             | 4.18±1.08  | 4.58±1.11       | 0.106   | 4.61±1.12  | 4.89±0.79       | 0.154   |
| Triglyceride (mmol/L)                  | 1.69±0.93  | 1.66±0.67       | 0.878   | 3.01±2.04  | 1.60±0.91       | 0.252   |
| HDL-C (mmol/L)                         | 1.13±0.32  | 1.08±0.33       | 0.516   | 1.12±0.29  | 1.32±0.59       | 0.047*  |
| LDL-C (mmol/L)                         | 2.35±0.82  | 2.57±0.99       | 0.281   | 2.67±0.91  | 2.75±0.66       | 0.643   |
| HbA1c (%)                              | 5.79±2.14  | 5.96±1.98       | 0.726   | 5.78±1.43  | 5.79±2.22       | 0.986   |
| White blood cell count (10^9/L)        | 5.95±1.90  | 6.47±1.62       | 0.200   | 6.35±2.27  | 6.41±1.92       | 0.896   |
| hsCRP (mg/L)                           | 11.17±5.27 | 11.87±6.35     | 0.714   | 5.36±4.44  | 7.14±6.76       | 0.321   |
| ProBNP (pg/mL)                         | 461.02±952.61 | 631.53±1,241.69 | 0.740   | 251.21±503.95 | 298.09±394.12 | 0.640   |
| **Medications**                        |            |                 |         |            |                 |         |
| Statins, n (%)                         | 13 (28.26%) | 6 (16.67%)      | 0.195   | 2 (4.17%)  | 3 (4.92%)       | 1.000   |
| Insulin, n (%)                         | 2 (4.35%)  | 1 (2.38%)       | 1.000   | 0          | 6 (9.84%)       | 0.033*  |
| ACEI/ARB, n (%)                        | 7 (15.56%) | 6 (14.29%)      | 0.905   | 10 (23.81%)| 4 (8.16%)       | 0.077   |
| CCB, n (%)                             | 8 (17.78%) | 11 (26.83%)     | 0.312   | 10 (23.81%)| 7 (14.29%)      | 0.245   |
| ß blocker, n (%)                       | 4 (8.89%)  | 2 (4.88%)       | 0.760   | 4 (9.52%)  | 1 (2.04%)       | 0.271   |
| **Cardiovascular history**             |            |                 |         |            |                 |         |
| ACS (%)                                | 13 (28.89%)| 13 (28.89%)     | 0.870   | 0          | 0               | 1.000   |
| Post-PCI or CABG (%)                   | 21 (45.65%)| 11 (28.95%)     | 0.117   | 0          | 0               | 1.000   |
| **Number of vascular lesions**         |            |                 |         |            |                 |         |
| 1                                      | 19 (41.30%)| 22 (52.38%)     | 0.582   |            |                 |         |
| 2                                      | 12 (26.09%)| 9 (21.43%)      |         |            |                 |         |
| ≥3                                     | 15 (32.61%)| 11 (26.19%)     |         |            |                 |         |
| **Degree of stenosis**                 |            |                 |         |            |                 |         |
| Lowly stenosis (50%≤ stenosis <75%)    | 16 (34.78%)| 23 (54.76%)     | 0.059   |            |                 |         |
| Highly stenosis (stenosis ≥75%)        | 30 (65.22%)| 19 (45.24%)     |         |            |                 |         |
| LVEF (%)                               | 61.8±13.2  | 55.8±21.7       | 0.152   | 59.9±16.5  | 50.6±27.2       | 0.046*  |

Continuous variables were described as mean ± standard deviation; categorical variables were presented as frequencies. CAD, coronary artery disease; n, number of patients; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycosylated haemoglobin; hsCRP, high sensitivity C reactive protein; proBNP, Pro-Brain Natriuretic Peptide; ACEI/ARB, angiotensin-converting enzyme inhibitor and angiotensin receptor block agent; CCB, calcium channel blocker; WBC, white blood cells count; post-PCI, post percutaneous coronary intervention; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; ACS, acute coronary syndrome. *, P<0.05.
groups. In the non-CAD group, more patients in the low-
vaspin subgroup experienced MACE as compared to that
in the high-vaspin subgroup [20 (41.67%), vs. 11 (19.30%);
\(P=0.012\)]. Especially, in this group, the low-vaspin subgroup
had a higher risk of stroke than that in the high-vaspin
subgroup [7 (14.58%) vs. 1 (1.75%); \(P=0.036\)] (Table 3).

### Relationship of plasma vaspin levels with prognosis

The Kaplan-Meier method was used to analyze the timing
of incidence of MACE during follow-up. Kaplan Meier
survival curves showed that patients in the low-vaspin group
had an obviously higher timing of incidence of MACE
in the whole population (log rank test 7.578, \(P=0.006\),
Figure 1). Notably, patients in the low-vaspin group had
a significantly higher timing of incidence of MACE as
compared to those in the high-vaspin group in the non-
CAD subgroup (log rank test 6.741, \(P=0.009\)). A similar
trend was observed in the CAD group, although it was not
statistically significant (log rank test 1.255, \(P=0.263\)). In the
CAD group, there were insignificant difference between
patients with vaspin <0.385 ng/mL and those with vaspin
>0.385 ng/mL both in lowly stenosis and highly stenosis
group (Figure S1).

### Multivariate analysis

After inclusion of clinical characteristics in the Cox
proportional hazards model, low vaspin levels (hazard
ratio, HR 0.387, \(P=0.001\)) and age (HR 1.034, \(P=0.012\))
independently predicted the occurrence of MACE. Furthermore,
in the non-CAD group, low vaspin levels
(HR 0.260, \(P=0.002\)), specify the gender (HR 2.920,
\(P=0.010\), age (HR 1.054, \(P=0.005\)) and TG levels (HR
0.462, \(P=0.044\)) were found to be independent predictors of
MACE (Table 4).

### Discussion

In this study, low plasma concentration of vaspin was

---

Table 3 Prognostic characteristics with 5 years MACEs between low and high vaspin subgroups

| Characteristics                  | CAD (n=84) | Non-CAD (n=105) |
|----------------------------------|-----------|-----------------|
|                                  | Vasin <0.385 | Vasin >0.385 | P value | Vasin <0.385 | Vasin >0.385 | P value |
| MACE, n (%)                      | 32 (38.10) | 31 (29.52) | 0.214 | 0.26 (41.67) | 74 (70.48) | 0.028* |
| 0                                | 52 (61.90) | 74 (70.48) | 0.028* |
| 1                                | 16 (19.75) | 21 (20.00) | 0.036* |
| 2                                | 3 (3.57) | 7 (6.67) | 0.880 |
| 3                                | 9 (10.71) | 3 (2.86) | 0.036* |
| 4                                | 4 (4.76) | 0 | 0.735 |
| New disease                      |           |                |        |
| Diabetes, n (%)                  | 3 (6.52) | 2 (5.26) | 1.000 | 3 (6.67) | 1 (1.75) | 0.492 |
| Hypertension, n (%)              | 0 | 0 | 1.000 | 1 (2.08) | 0 | 0.457 |
| Total MACE, n (%)                | 20 (43.48) | 12 (31.58) | 0.264 | 20 (41.67) | 11 (19.30) | 0.012* |
| Cardiac death, n (%)             | 2 (4.35) | 3 (7.89) | 0.825 | 2 (4.17) | 1 (1.75) | 0.880 |
| Non-fatal myocardial infarction, n (%) | 6 (13.04) | 7 (18.42) | 0.498 | 3 (6.25) | 5 (8.77) | 0.908 |
| Revascularization, n (%)         | 13 (28.26) | 3 (7.89) | 0.018* | 2 (4.17) | 3 (5.26) | 1.000 |
| Stroke, n (%)                    | 5 (10.87) | 3 (7.89) | 0.929 | 7 (14.58) | 1 (1.75) | 0.036* |
| Rehospitalisation, n (%)         | 13 (28.26) | 10 (26.32) | 0.842 | 11 (22.92) | 9 (15.79) | 0.354 |
| All-cause death, n (%)           | 4 (8.70) | 4 (10.53) | 1.000 | 4 (8.33) | 7 (12.28) | 0.735 |

Categorical variables were presented as frequencies. n, number of patients. *, P<0.05.
found to predict the prognosis of patients after CAG. Furthermore, we found that low vaspin level could predict the prognosis in non-CAD patients. On Cox regression analysis, low vaspin level was found to be an independent risk factor for MACE.

In a study by Kameshima et al., vaspin was showed to prevent the increase in SBP, an effect that was attributed to its antioxidant and anti-inflammatory roles in smooth muscle cells of peripheral blood vessels (21). In addition, vaspin was indicated to protect vascular endothelial cells from free fatty acid induced apoptosis through up-regulation of the PI3-kinase/Akt signaling pathway (22). Further, administration of vaspin to diet-induced obese mice was showed to improve glucose tolerance, insulin sensitivity, and to alter the expression of genes implicated in the causation of insulin resistance (3,23). Also, vaspin prevented myocardial injury in rats model of diabetic cardiomyopathy by suppressing NLRP3 inflammasome activation and promoting autophagy (24). Besides, it was reported that statin therapy could increases plasma vaspin levels (25). All these studies suggest a protective effect of vaspin on vascular biology as well as that against insulin resistance. Some other reports also showed a correlation between vaspin levels and atherosclerotic lesions. An early study demonstrated that serum vaspin level was positively associated with carotid intima-media thickness (26). Further, in a study by Kameshima et al., vaspin was showed to suppress inflammatory phenotypes by down-regulating NF-κB in human macrophages and oxidized low-density lipoprotein-induced foam cell formation (27).

Although experimental studies have indicated that vaspin is a vasculoprotective adipocytokine, its' specific role and clinical relevance in CAD is not clear (28). In this study, presence of risk factors for CAD (such as hypertension, hyperlipidemia and diabetes) was not different between low- and high -vaspin subgroups, both in the CAD and non-CAD groups; this suggests that vaspin may be a more sensitive biomarker for atherosclerosis such as CAD. In the follow-up study, we found that patients with high vaspin levels had improved cardiac function, which suggests that patients with high vaspin levels may have a better prognosis. In addition, increased incidence of MACE may also be attributable to development of co-morbid conditions such as diabetes and hypertension. However, we did not find any significant increase in new onset diabetes or hypertension in both CAD and non-CAD groups; this implied that increase in the incidence of MACE was associated with decreased vaspin levels, and was not due to new-onset diabetes or hypertension. Gulcelik et al. found that plasma vaspin levels in diabetic patients with chronic complications (including retinopathy and nephropathy) were lower than those in their counterparts without complications (29). In our previous study, low plasma concentration of vaspin was found to be a risk factor for progression of T2DM (4). These results

**Figure 1** The Kaplan-Meier method was used to analyse the timing of incidence of MACEs during follow-up. (A) Patients with vaspin <0.385 ng/mL had a significantly higher timing of incidence of MACE than those with vaspin >0.385 ng/mL group (log rank test 7.578, P=0.006) in the whole population; (B) patients with low vaspin had a significantly higher timing of incidence of MACE than those with high vaspin (log rank test 6.741, P=0.009) in the non-CAD group; (C) there were insignificant between two groups (log rank test 1.255, P=0.263) in the CAD group.
indicated that diabetic patients with low vaspin levels may have poorer outcomes and higher prevalence of micro- or macro-vascular complications over the longer term.

The exact reasons for the variability in plasma vaspin concentrations remain debatable. In the present study, we focus on the prognostic value of vaspin in patients with non-CAD; our findings suggest that vaspin plays an important role in the complex function of organism. In our previous study, we found decreased plasma vaspin levels in patients with CAD and those with severe ischemic symptoms (12,13). In clinical settings, some “vulnerable patients” who present with chest pain but who exhibit negative findings on CAG may not be correctly diagnosed as patients with “vulnerable plaque”. In our previous study, the average plasma vaspin concentration among patients in the non-CAD group who experienced a MACE (0.43 ng/mL) was far lower than that in the healthy population (1.78 ng/mL) (30). Patients with negative CAG and low concentration of vaspin are at an increased risk of MACE and need more care.

The study limitations include its retrospective nature, which may introduce an element of recall bias. Furthermore, the sample size of this study is also relatively small. Finally, this was a single-institution study and, as such, requires external validation. However, to our knowledge, the follow-up time is sufficient enough and the study confirmed the predictive value of plasma vaspin for future cardiovascular events in patients, particularly in the non-CAD group. This parameter warrants further validation as a potential selection criterion for risk factor-stratified patient management in the non-CAD population.

### Table 4 Univariate and multivariate analyses of predictors of MACEs in total subjects and non-CAD group

| Variable                      | Hazard ratio | 95% CI      | P value |
|-------------------------------|--------------|-------------|---------|
| **Model for total subjects**  |              |             |         |
| Univariate analysis           |              |             |         |
| Vaspin                        | 0.494        | 0.295–0.825 | 0.007   |
| Gender                        | 1.560        | 0.951–2.558 | 0.078   |
| Age                           | 1.050        | 1.024–1.077 | <0.001  |
| Triglyceride (mmol/L)         | 0.681        | 0.465–0.997 | 0.048   |
| Multivariate analysis         |              |             |         |
| Vaspin (ng/mL)                | 0.387        | 0.220–0.679 | 0.001   |
| Gender                        | 1.673        | 0.981–2.852 | 0.059   |
| Age                           | 1.034        | 1.007–1.061 | 0.012   |
| Triglyceride (mmol/L)         | 0.678        | 0.455–1.010 | 0.056   |
| **Model for non-CAD group**   |              |             |         |
| Univariate analysis           |              |             |         |
| Vaspin                        | 0.390        | 0.187–0.815 | 0.012   |
| Gender                        | 2.346        | 1.123–4.900 | 0.023   |
| Age                           | 1.079        | 1.040–1.119 | <0.001  |
| Triglyceride (mmol/L)         | 0.509        | 0.261–0.992 | 0.047   |
| Multivariate analysis         |              |             |         |
| Vaspin (ng/mL)                | 0.260        | 0.109–0.618 | 0.002   |
| Gender                        | 2.920        | 1.290–6.613 | 0.010   |
| Age                           | 1.054        | 1.016–1.094 | 0.005   |
| Triglyceride (mmol/L)         | 0.462        | 0.218–0.980 | 0.044   |

MACEs, major adverse major cardiac events; CI, confidence interval.
Conclusions

Plasma vaspin may prove to be a clinically relevant biomarker for prediction of future cardiovascular events in patients, particularly in those with no evidence of CAD on coronary angiography. In this study, patients with low vaspin levels were at a higher risk of a MACE.

Acknowledgments

Funding: This study is supported by grants from the Chinese National Natural Science Foundation No. 81670746, 81702091, 81670230 and Youth Foundation of Shanghai Pudong Gongli Hospital No. 2018QNJJ-14.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.29). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of Shanghai Tenth People's Hospital (SHSY-IEC-4.0/17-110/01) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Gao H, Fall T, van Dam RM, et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 2013;62:1338-44.
2. Ahlstrom P, Rai E, Chakma S, et al. Adiponectin improves insulin sensitivity via activation of autophagic flux. J Mol Endocrinol 2017;59:339-50.
3. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-5.
4. Jian W, Peng W, Xiao S, et al. Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study. PLoS One 2014;9:e94763.
5. El-Lebedy DH, Ibrahim AA, Ashmawy IO. Novel adipokines vaspin and irisin as risk biomarkers for cardiovascular diseases in type 2 diabetes mellitus. Diabetes Metab Syndr 2018;12:643-8.
6. Ostrowska Z, Ziora K, Osowiecimska J, et al. Vaspin and selected indices of bone status in girls with anorexia nervosa. Endokrynol Pol 2016;67:599-606.
7. Kohan L, Zarei A, Fallahi S, et al. Association between vaspin rs2236242 gene polymorphism and polycystic ovary syndrome risk. Gene 2014;539:209-12.
8. Bao JP, Jiang LF, Chen WP, et al. Expression of vaspin in the joint and the levels in the serum and synovial fluid of patients with osteoarthritis. Int J Clin Exp Med 2014;7:3447-53.
9. Chang HM, Lee HJ, Park HS, et al. Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity (Silver Spring) 2010;18:2105-10.
10. Wang H, Chen F, Li J, et al. Vaspin antagonizes high fat-induced bone loss in rats and promotes osteoblastic differentiation in primary rat osteoblasts through Smad-Runx2 signaling pathway. Nutr Metab (Lond) 2020;17:9.
11. Liu S, Duan R, Wu Y, et al. Effects of Vaspin on Insulin Resistance in Rats and Underlying Mechanisms. Sci Rep 2018;8:13542.
12. Zhang B, Peng W, Li H, et al. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin Biochem 2013;46:1520-5.
13. Li HL, Peng WH, Cui ST, et al. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin Chem Lab Med 2011;49:1547-54.
14. Zhang B, Peng W, Wang K, et al. Vaspin as a Prognostic Marker in Patients with Acute Myocardial Infarction. Heart Lung Circ 2016;25:257-64.
15. Li H, Peng W, Zhuang J, et al. Vaspin attenuates high
glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-kappa B signaling pathways. Atherosclerosis 2013;228:61-8.

16. Yuan L, Dai X, Fu H, et al. Vaspin protects rats against myocardial ischemia/reperfusion injury (MIRI) through the TLR4/NF-κB signaling pathway. Eur J Pharmacol 2018;835:132-9.

17. Hadamitzky M, Freissmuth B, Meyer T, et al. Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. JACC Cardiovasc Imaging 2009;2:404-11.

18. Zhang YJ, Iqbal J, van Klaveren D, et al. Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol 2015;65:1107-15.

19. Wolk R, Berger P, Lennon RJ, et al. Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 2003;108:2206-11.

20. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.

21. Kameshima S, Sakamoto Y, Okada M, et al. Vaspin prevents elevation of blood pressure through inhibition of peripheral vascular remodelling in spontaneously hypertensive rats. Acta Physiol (Oxf) 2016;217:120-9.

22. Jung CH, Lee WJ, Hwang JY, et al. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 2011;413:264-9.

23. Nakatsuka A, Wada J, Iseda I, et al. Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes 2012;61:2823-32.

24. Li X, Ke X, Li Z, et al. Vaspin prevents myocardial injury in rats model of diabetic cardiomyopathy by enhancing autophagy and inhibiting inflammation. Biochem Biophys Res Commun 2019;514:1-8.

25. Al-Azzam SI, Alzoubi KH, Abeeleh JA, et al. Effect of statin therapy on vaspin levels in type 2 diabetic patients. Clin Pharmacol 2013;5:33-8.

26. Esaki E, Adachi H, Hirai Y, et al. Serum vaspin levels are positively associated with carotid atherosclerosis in a general population. Atherosclerosis 2014;233:248-52.

27. Sato K, Shirai R, Yamaguchi M, et al. Anti-Atherogenic Effects of Vaspin on Human Aortic Smooth Muscle Cell/ Macrophage Responses and Hyperlipidemic Mouse Plaque Phenotype. Int J Mol Sci 2018;19.

28. Dimova R, Tankova T. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. Biomed Res Int 2015;2015:823481.

29. Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009;160:65-70.

30. Xu X, Wen J, Lu Y, et al. Impact of age on plasma vaspin concentration in a group of normal Chinese people. J Endocrinol Invest 2017;40:143-51.

Cite this article as: Ji S, Kou W, Luan P, Jian W, Zhuang J, Xu X, Zhao Y, Li H, Peng W. Plasma vaspin is an effective biomarker for evaluation of future cardiovascular events in patients with chest pain: a 5-year retrospective observational study. Ann Transl Med 2020;8(7):479. doi: 10.21037/atm.2020.03.29

© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2020;8(7):479 | http://dx.doi.org/10.21037/atm.2020.03.29
Table S1 Variation of serum lipid level and Echocardiography during 5 years between low and high vaspin subgroups

| Variable                        | CAD (n=84) | Non-CAD (n=105) |
|---------------------------------|------------|-----------------|
|                                 | Baseline   | Follow-up       | Baseline   | Follow-up       | Baseline   | Follow-up       | Baseline   | Follow-up       | Baseline   | Follow-up       | P value | Baseline   | Follow-up       | P value | Baseline   | Follow-up       | P value | Baseline   | Follow-up       | P value | Baseline   | Follow-up       | P value |
|                                 |            |                 |            |                 |            |                 |            |                 |            |                 |         |            |                 |         |            |                 |         |            |                 |         |            |                 |         |
| Laboratory data                 |            |                 |            |                 |            |                 |            |                 |            |                 |         |            |                 |         |            |                 |         |            |                 |         |            |                 |         |
| Total cholesterol (mmol/L)      | 4.18±1.08  | 4.00±0.97       | 0.396      | 4.64±1.13       | 4.04±1.08  | 0.035*          | 4.61±1.12  | 4.51±0.93       | 0.688      | 4.85±0.79     | 4.56±1.32     | 0.204      |         |                 |         |            |                 |         |            |                 |         |
| Triglyceride (mmol/L)           | 1.69±0.93  | 1.73±1.13       | 0.863      | 1.63±0.66       | 1.58±0.65  | 0.777           | 3.01±0.04  | 1.50±0.95       | 0.319      | 1.56±0.85     | 1.36±0.79     | 0.244      |         |                 |         |            |                 |         |            |                 |         |
| LDL-C (mmol/L)                  | 2.35±0.83  | 2.17±0.79       | 0.309      | 2.63±0.99       | 2.32±0.85  | 0.199           | 2.67±0.91  | 2.53±0.80       | 0.469      | 2.72±0.66     | 2.74±1.06     | 0.911      |         |                 |         |            |                 |         |            |                 |         |
| HDL-C (mmol/L)                  | 1.13±0.32  | 1.09±0.28       | 0.510      | 1.11±0.33       | 1.00±0.22  | 0.130           | 1.12±0.29  | 1.21±0.31       | 0.225      | 1.33±0.61     | 1.16±0.33     | 0.117      |         |                 |         |            |                 |         |            |                 |         |
| HbA1c (%)                       | 5.79±2.14  | 6.42±1.29       | 0.235      | 5.69±1.48       | 6.41±1.08  | 0.061           | 5.78±1.43  | 6.03±0.90       | 0.490      | 5.79±2.22     | 7.01±1.94     | 0.033*      |         |                 |         |            |                 |         |            |                 |         |
| Echocardiography                |            |                 |            |                 |            |                 |            |                 |            |                 |         |            |                 |         |            |                 |         |            |                 |         |
| LVEF (%)                        | 61.8±13.2  | 62.2±11.2       | 0.864      | 55.8±21.7       | 64.5±9.1   | 0.026*          | 59.9±16.5  | 64.7±8.7        | 0.102      | 50.6±27.2     | 65.1±6.2      | <0.001*     |         |                 |         |            |                 |         |            |                 |         |
| Internal diameter of aortic sinus (mm) | 34.33±2.9934.08±3.34 | 0.759 | 33.19±3.55 | 32.18±8.60 | 0.563 | 33.74±3.43 | 33.90±2.61 | 0.846 | 32.05±3.33 | 34.31±5.92 | 0.082 |         |                 |         |            |                 |         |            |                 |         |
| Left atrial diameter (mm)       | 42.92±5.6841.83±6.26 | 0.479 | 42.69±5.63 | 42.71±7.16 | 0.992 | 42.39±6.11 | 42.43±5.47 | 0.983 | 40.24±5.50 | 42.00±6.38 | 0.314 |         |                 |         |            |                 |         |            |                 |         |
| Left ventricular end diastole (mm) | 48.97±6.5048.70±6.38 | 0.850 | 48.50±5.55 | 48.26±5.75 | 0.866 | 48.00±3.70 | 48.10±4.94 | 0.918 | 47.03±3.48 | 46.11±3.90 | 0.294 |         |                 |         |            |                 |         |            |                 |         |
| Left ventricular end systole (mm) | 33.23±7.8132.04±8.61 | 0.575 | 31.56±6.60 | 31.71±8.32 | 0.948 | 31.08±4.32 | 30.10±4.13 | 0.850 | 29.46±3.02 | 29.50±4.53 | 0.970 |         |                 |         |            |                 |         |            |                 |         |
| Interventricular septal thickness (mm) | 9.44±1.23 | 9.58±1.14 | 0.637 | 9.91±2.32 | 9.65±1.22 | 0.670 | 9.58±1.08 | 10.05±1.24 | 0.136 | 9.22±1.13 | 9.94±1.81 | 0.084 |         |                 |         |            |                 |         |            |                 |         |
| Left ventricular posterior wall thickness (mm) | 9.41±1.04 | 9.25±0.90 | 0.535 | 9.19±0.86 | 9.35±0.93 | 0.536 | 9.34±0.94 | 9.67±1.02 | 0.222 | 8.95±0.91 | 9.50±1.71 | 0.130 |         |                 |         |            |                 |         |            |                 |         |

Continuous variables were described as mean ± standard deviation; categorical variables were presented as frequencies. n, number of patients; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycosylated haemoglobin; LVEF, left ventricular ejection fraction. *, P<0.05.
Figure S1 There were insignificant differences between patients with vaspin <0.385 ng/mL and those with vaspin >0.385 ng/mL both in lowly stenosis (P=0.159) and highly stenosis group (P=0.977).